Anika Therapeutics Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Stephen D. Griffin
- Full Time Employees
- 235
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 32 Wiggins Avenue Bedford MA United States 01730
- IPO Date
- May 16, 1985
- CIK
- 0000898437
- Website
- anika.com
- Similar Companies
- Business
- Anika Therapeutics, Inc. is a global joint preservation company specializing in early intervention orthopedic care. The company develops, manufactures, and commercializes therapeutic products designed for osteoarthritis (OA) pain management, regenerative solutions, and sports medicine. Its core product portfolio is based on its proprietary hyaluronic acid (HA) technology platform, including OA pain management injectables such as Monovisc and Orthovisc, and the next-generation single-injection product Cingal, which combines cross-linked HA with a steroid. Anika’s regenerative solutions include the Integrity Implant System, an HA-based scaffold for rotator cuff and tendon repairs, as well as other orthopedic implants and instruments like the X-Twist Fixation System. The company also markets advanced shoulder arthroplasty systems supported by preoperative planning software. Founded in 1996 and headquartered in Bedford, Massachusetts, Anika operates globally with a significant presence in the United States and international markets. The company targets orthopedic surgeons, sports medicine specialists, and healthcare providers focusing on joint preservation and repair. Recent major changes include the strategic divestiture of the Arthrosurface business in October 2024 and the completed sale of Parcus Medical to Medacta Group SA in March 2025, enabling Anika to concentrate fully on its core hyaluronic acid technology and expanding Regenerative Solutions portfolio. Additionally, in 2024, Anika launched several new products including the Integrity Implant System and X-Twist Fixation System, and advanced its FDA regulatory filings for Hyalofast, a proprietary HA scaffold for cartilage repair with U.S. market launch anticipated by 2026. The company’s strategic focus is on profitable growth through its HA-driven OA pain management products and high growth regenerative solutions. Anika Therapeutics leverages a technology-driven approach within the healthcare equipment and supplies industry, dedicating resources to innovation in minimally invasive orthopedic products and early intervention treatments, positioning itself as a leader in joint preservation and restoring active mobility worldwide.
Company News
Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript
What Anika Therapeutics (ANIK) Said on Its Q3 Earnings Call
Anika Therapeutics (ANIK) Beats Q3 Earnings and Revenue Estimates
Anika Reports Third Quarter 2026 Financial Results
Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026
Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?
Xencor (NASDAQ:XNCR) versus Anika Therapeutics (NASDAQ:ANIK) Head-To-Head Contrast
Corient Private Wealth LP Takes Position in Anika Therapeutics Inc. $ANIK
Hsbc Holdings PLC Invests $727,000 in Anika Therapeutics Inc. $ANIK
Best Momentum Stocks to Buy for August 26th
Anika (ANIK) Is a Great Choice for 'Trend' Investors, Here's Why
Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?
5 Stocks With Recent Price Strength to Enhance Your Portfolio Returns
Anika Therapeutics (ANIK) Is Up 11.10% in One Week: What You Should Know
5 Stocks With Recent Price Strength to Tap August Rally
Anika (ANIK) is on the Move, Here's Why the Trend Could be Sustainable
Anika Therapeutics, Inc. (ANIK) Q2 2026 Earnings Call Transcript
Anika Therapeutics Q2 Earnings Call Highlights
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)